{"id":967027,"date":"2026-05-26T16:16:27","date_gmt":"2026-05-26T20:16:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/"},"modified":"2026-05-26T16:16:27","modified_gmt":"2026-05-26T20:16:27","slug":"delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/","title":{"rendered":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts<\/b><\/p>\n<p>QUEENSBURY, N.Y.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath\u2019s percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT\u2122 Hepatic Delivery System (HDS) in metastatic melanoma involving the liver \u2014 a common and difficult-to-treat site of disease progression.<\/p>\n<p>\nOne abstract, titled <i>&#8220;Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan\/hepatic delivery system followed by tebentafusp in the treatment of metastatic uveal melanoma,&#8221;<\/i> describes an investigator-initiated Phase 2 trial evaluating sequential treatment with HEPZATO followed by tebentafusp in patients with metastatic uveal melanoma (mUM) who are HLA-A*02:01 positive and have isolated or liver-dominant metastases. The study is designed to assess progression-free survival and additional measures including safety, objective response, overall survival, and biomarker analyses. The study opened for enrollment in November 2025.<\/p>\n<p>\nA second abstract, titled <i>&#8220;Phase 1b\/2 trial of melphalan-percutaneous hepatic perfusion (PHP) therapy and nivolumab\/relatlimab in patients with metastatic melanoma and liver metastasis,&#8221;<\/i> outlines a single-center Phase 1b\/2 study evaluating HEPZATO in combination with nivolumab\/relatlimab as a first-line treatment approach for patients with metastatic non-uveal melanoma involving the liver. The trial is intended to assess safety, tolerability, and preliminary efficacy, with secondary objectives including disease control rate, progression-free survival, overall survival, duration of response, and tumor reduction. The study opened for enrollment in January 2026.<\/p>\n<p>\nThe abstract on sequential PHP followed by tebentafusp in mUM (Abstract TPS9605) and the abstract on PHP plus nivolumab\/relatlimab in metastatic melanoma with liver metastasis (Abstract TPS9600) will be presented as posters at the 2026 ASCO Annual Meeting. Specific session details will be available on the ASCO website.<\/p>\n<p>\n\u201cWe believe the publication of these two ASCO abstracts underscores the growing clinical interest in HEPZATO\u2019s potential across multiple metastatic melanoma settings with liver involvement,\u201d said Gerard Michel, Chief Executive Officer of Delcath Systems. \u201cThese investigator-initiated trials will provide important insights into combining or sequencing liver-directed therapy with modern systemic treatments in patients with challenging disease. We remain committed to supporting such research to advance therapeutic options for patients with liver cancers and metastases.\u201d<\/p>\n<p><b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT<\/b><\/p>\n<p>\nDelcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company\u2019s proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection\/Hepatic Delivery System) and CHEMOSAT<sup>\u00ae<\/sup> Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.<\/p>\n<p>\nIn the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath\u2019s proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure.<\/p>\n<p>\nHEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING, for <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hepzatokit.com&amp;esheet=54542142&amp;newsitemid=20260526453584&amp;lan=en-US&amp;anchor=HEPZATO+KIT&amp;index=1&amp;md5=14ba310929bb1e61b26fcbb2bbb4302c\">HEPZATO KIT<\/a>.<\/p>\n<p>\nIn Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260526453584\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260526453584\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact:<br \/>\n<\/b><br \/>ICR Healthcare<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investorrelations@delcath.com\">investorrelations@delcath.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Medical Devices Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260526453584\/en\/2815267\/3\/Delcath_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts QUEENSBURY, N.Y.&#8211;(BUSINESS WIRE)&#8211; Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath\u2019s percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT\u2122 Hepatic Delivery System (HDS) in metastatic melanoma involving the liver \u2014 a common and difficult-to-treat site of disease progression. One abstract, titled &#8220;Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan\/hepatic delivery system &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967027","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts QUEENSBURY, N.Y.&#8211;(BUSINESS WIRE)&#8211; Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath\u2019s percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT\u2122 Hepatic Delivery System (HDS) in metastatic melanoma involving the liver \u2014 a common and difficult-to-treat site of disease progression. One abstract, titled &#8220;Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan\/hepatic delivery system &hellip; Continue reading &quot;Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T20:16:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts\",\"datePublished\":\"2026-05-26T20:16:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/\",\"name\":\"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-26T20:16:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/","og_locale":"en_US","og_type":"article","og_title":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk","og_description":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts QUEENSBURY, N.Y.&#8211;(BUSINESS WIRE)&#8211; Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath\u2019s percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT\u2122 Hepatic Delivery System (HDS) in metastatic melanoma involving the liver \u2014 a common and difficult-to-treat site of disease progression. One abstract, titled &#8220;Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan\/hepatic delivery system &hellip; Continue reading \"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-26T20:16:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts","datePublished":"2026-05-26T20:16:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/","name":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-26T20:16:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526453584r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-announces-two-asco-2026-investigator-initiated-trials-in-progress-abstracts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967027"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967027\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}